AssayIndex

AX-2026-042374

Semax · 20 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2601-D3090

MARGINALVERIFIED
Report ID
AX-2026-042374
Compound
Semax
Compound class
Neuroactive and cognitive peptides
Supplier
Homopeptide — Hunan Aslsen Technology Co., Ltd.
Batch / lot
HOMO-2601-D3090
Declared label claim
20mg
Laboratory
Janoshik Analytical
Assay date
16 Jan 2026
Submitted
21 Jan 2026
Quarter
2026-Q1
Submitter
ah.okwuosa
Sample provenance
Supplier-supplied
Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 30 min gradient, 214 nm99.50% area≥ 98.5PASS
Total impuritiesRP-HPLC, sum of reported peaks0.50% area≤ 1.5PASS
Largest single impurityRP-HPLC — diketopiperazine (−18 Da)0.27% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula813.3541Da—NOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)813.3582Da—NOT TESTED
Mass accuracyobserved vs theoretical+5.1ppm± 15PASS
Total peptide contentby difference from the gravimetric mass balance84.31%w/w—NOT TESTED
Target-compound contenttotal peptide content × purity83.89%w/w—NOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen22.77mg20 mg declaredNOT TESTED
Recovered target peptidegross fill × target content19.102mg20 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim95.5%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate7.56%≤ 12.0PASS
Counter-ion (acetate)anion-exchange ion chromatography7.80%≤ 10.0PASS
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.33%—NOT TESTED
Endotoxinkinetic chromogenic LAL0.55EU/mg≤ 5.0PASS
Sterilitynot ordered on this submissionnot determined—no growthNOT TESTED
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intact—white to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear, colourless, no visible particulates—clear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration4.96—2.5 – 8.0PASS
Retention time (observed)RP-HPLC, 30 min gradient7.93min7.06 ± 0.25 (normalised)FAIL
Peak asymmetry (10 % height)Ph. Eur. 2.2.461.03—0.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²83,550—≥ 20,000PASS
Resolution to nearest impurityvs diketopiperazine (−18 Da)1.42—no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

0413682721240916545 Semax7.93 min · 99.50 % 8.09 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 83,550, and skew follows the reported asymmetry factor of 1.03. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.27 % impurity against a 99.50 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1Semax — main peak7.934,836,00899.50—
2diketopiperazine (−18 Da)8.0913,1230.27-18.011
3Met1 sulfoxide (+16 Da)7.576,3180.13+15.995
4N-acetyl semax (+42 Da)8.352,9160.06+42.011
5des-Met (−131 Da)8.131,9440.04-131.040
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 813.3541 Da, computed from C37H51N9O10S. All ppm figures on this site are against monoisotopic values — see why that matters.

0255075100350450550650750850 [M+1H]1+814.37[M+2H]2+407.69 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 813.3582 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
2+407.6843407.68640.002156.5
1+814.3614814.36550.0041100.0
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer7.56
Counter-ion (acetate)ion chromatography7.80
Residual solvent + inorganic residueestimated0.33
Total peptide contentby difference84.31
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)98.9899.50divergence +0.08 pp vs batch median
Total impurities (% area)not stated0.50
Largest single impurity (% area)not stated0.27
Water (%)not stated7.56
Counter-ion (%)not stated7.80
Peptide content (%w/w)91.784.31
Endotoxin (EU/mg)0.190.55
Method stated on certificateNO—no method section — the result cannot be reconciled against any other
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Supplier-supplied
Evidentiary weight
Weaker evidence. Read with the caveat below.
Chain of custody
Supplier despatch → laboratory direct (courier, cold pack, 2 d) → assay. Submitter did not handle the vial.
Assay date
16 Jan 2026
Submitted to the index
21 Jan 2026
Laboratory
Janoshik Analytical, Ostrava, Czechia
Method basis
30 min gradient · high-resolution MS
Verification status
VERIFIED
Section 6

Annotations 5

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

sig_figs
Two decimal places on 99.50 % implies repeatability better than 0.01 pp, which no laboratory here claims. The number is sound; the printed precision is more than the method carries.
Index data team

Two decimal places are retained because the source reports carry them and truncating would discard information where a laboratory genuinely reports it. The uncertainty budget on /methods/uncertainty-budget/ is the right thing to read alongside any purity figure on this site.

ppm_error
Mass, retention and impurity profile all agree on this record. Three independent constraints pointing the same way is the strongest identity evidence the index publishes.
buyer_sourced
An independently purchased vial from the same lot would convert this record from indicative to decisive. Buyer-sourced material is roughly 87 % of the index and it should be all of it.
one_directional
The provenance effect is a mean, and means conceal tails. Rule AX-R10 exists for the individual lots where the paired gap is large, and it fires rarely.
json_ld_ax
Adding a note that I have seen this pattern before and had nothing to add at the time.
Section 7

Related records

Same batch — lot HOMO-2601-D3090 n=7

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042368HOMO-2601-D3090PeptideMeter2026-Q199.057.0498.2Buyer-sourced1MARGINAL
AX-2026-042369HOMO-2601-D3090Janoshik2026-Q198.876.90102.6Buyer-sourced2MARGINAL
AX-2026-042370HOMO-2601-D3090VendorInvestigate2026-Q199.117.29—Buyer-sourced1MARGINAL
AX-2026-042371HOMO-2601-D3090Nordanalyt2026-Q198.566.6791.3Buyer-sourced1MARGINAL
AX-2026-042372HOMO-2601-D3090Janoshik2026-Q198.896.58—Buyer-sourced1MARGINAL
AX-2026-042373HOMO-2601-D3090Janoshik2026-Q198.907.61—Buyer-sourced1MARGINAL

Cross-sections

Other recent Semax records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042519HomopeptideHOMO-2605-S5227Medutest2026-Q399.755.55—Buyer-sourced0PASS
AX-2026-042517HomopeptideHOMO-2605-S5227Janoshik2026-Q399.925.88—Buyer-sourced0PASS
AX-2026-042518HomopeptideHOMO-2605-S5227Janoshik2026-Q399.765.61—Buyer-sourced0PASS
AX-2026-042524HomopeptideHOMO-2605-S5227Janoshik2026-Q399.935.75100.9Supplier-supplied0PASS
AX-2026-042516HomopeptideHOMO-2605-S5227Janoshik2026-Q399.935.8795.1Buyer-sourced0PASS
AX-2026-042522HomopeptideHOMO-2605-S5227Nordanalyt2026-Q399.935.49—Buyer-sourced0PASS
AX-2026-042520HomopeptideHOMO-2605-S5227Medutest2026-Q399.936.12—Buyer-sourced0PASS
AX-2026-042514HomopeptideHOMO-2605-S5227Janoshik2026-Q399.595.4897.0Buyer-sourced0PASS
Other recent Homopeptide records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042437RetatrutideHOMO-2605-V4718Nordanalyt2026-Q398.683.67102.8Buyer-sourced0PASS
AX-2026-042424SemaglutideHOMO-2604-X3806PeptideMeter2026-Q398.854.8792.0Buyer-sourced0PASS
AX-2026-042503IGF-1 LR3HOMO-2607-P5131Janoshik2026-Q399.365.99—Buyer-sourced0PASS
AX-2026-042492SS-31 (Elamipretide)HOMO-2604-D5484Medutest2026-Q399.932.40—Buyer-sourced0PASS
AX-2026-042491SS-31 (Elamipretide)HOMO-2604-D5484Kestrel2026-Q399.933.24—Supplier-supplied0PASS
AX-2026-042473LL-37HOMO-2602-G5165Janoshik2026-Q399.015.00—Buyer-sourced0PASS
AX-2026-042441RetatrutideHOMO-2605-V4718Medutest2026-Q398.934.22—Buyer-sourced0PASS
AX-2026-042474LL-37HOMO-2602-G5165Janoshik2026-Q399.185.44—Buyer-sourced0PASS